Consumer health company Haleon (LSE: HLN) and Brightseed, a pioneer in AI-driven discovery of bioactive compounds, will collaborate to advance the discovery of plant-based, small molecules with the potential to improve human health, the companies announced.

This partnership will leverage Brightseed’s proprietary AI platform, Forager, as a solution to accelerate scientific insights into the natural world and support Haleon’s mission to deliver innovative, science-led health solutions. The Forager platform maps bioactives and identifies their mechanisms of action.

In addition to this collaboration agreement, Brightseed will work with Haleon to make Forager directly accessible to Haleon’s scientists, enabling efficient natural bioactive discovery by integrating AI-powered discovery into their research and product development pipelines. 

“We are thrilled with this partnership that augments our scientific capabilities towards groundbreaking advancements,” said Sandrine Alvarado, vice president and head of future horizons R&D at Haleon. “This collaboration is pivotal in accelerating discoveries and innovations that are firmly rooted in superior, trusted science and the highest standards of scientific integrity.” 

Brightseed’s AI-driven approach to bioactive discovery has yielded key insights into plant compounds with potential applications across metabolic health, gut health, immunity, and more. This collaboration aligns with Haleon’s commitment to science-backed innovation and the pursuit of next-generation natural health solutions. 

“Forager’s AI not only accelerates innovation, it also expands possibilities in ways that would have been otherwise intractable,” said Lee Chae, co-founder and CEO at Brightseed. “With this collaboration, Haleon is poised to translate those possibilities into an engine for growth.”